Session » Osteoarthritis – Clinical Poster II

Date: Monday, November 18, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 2099

A Longitudinal Study of Infrapatellar Fat Pad Morphologies as Predictive Markersin Knee Osteoarthritis

10:30AM-12:30PM: Abstract Number: 2096

A Model Based on Clinical and Molecular Data Predcits the Risk of Total Joint Replacement Progression in Knee OA Patients from the OAI

10:30AM-12:30PM: Abstract Number: 2108

A Pilot Randomized Controlled Trial for Hand Osteoarthritis

10:30AM-12:30PM: Abstract Number: 2111

An International Patient Survey to Identify Candidate Items for Classifying Early-Stage Symptomatic Knee Osteoarthritis

10:30AM-12:30PM: Abstract Number: 2097

Application of Machine Learning Methods to Predict the Risk of Rapid Pain Progression in Patients with Knee OA. Study Using Patients from the OAI and PROCOAC

10:30AM-12:30PM: Abstract Number: 2110

Association Between Symptomatic Knee Osteoarthritis and Blood Glucose Control in Persons with Type 2 Diabetes

10:30AM-12:30PM: Abstract Number: 2087

Association of MRI-Defined Structure Features at Baseline with Knee Pain and Function Trajectories: Data from the Osteoarthritis Initiative (OAI)

10:30AM-12:30PM: Abstract Number: 2091

Changes in Analgesic Prescriptions for the Treatment of Osteoarthritis During the COVID-19 Pandemic

10:30AM-12:30PM: Abstract Number: 2094

Cross-sectional Associations of Radiographic Multiple Joint Osteoarthritis and Pain with Demographic and Clinical Characteristics: Design of a Multi-modal Study in Human and Pet Dogs

10:30AM-12:30PM: Abstract Number: 2107

Deep Immunophenotyping of Knee Osteoarthritis Patients Reveals Alterations in T Cell, Treg, and Monocyte Subpopulations

10:30AM-12:30PM: Abstract Number: 2089

Diagnostic Performance of ACR and NICE Criteria for Hip Osteoarthritis

10:30AM-12:30PM: Abstract Number: 2106

EP-104IAR (Long-Acting Intra-Articular Injection of Fluticasone Propionate) Shows Sustained Improvement in Pain for Subjects with Moderate Baseline Pain and BMI Less Than 30 in SPRINGBOARD, a Phase 2, Randomized, 24-Week Study of Osteoarthritis of the Knee

10:30AM-12:30PM: Abstract Number: 2100

Exploring the Association Between Basketball Participation and Knee Osteoarthritis: Data from the Osteoarthritis Initiative

10:30AM-12:30PM: Abstract Number: 2101

Patient Characteristics Associated with Objectively-Assessed Physical Activity in Veterans with Knee Osteoarthritis

10:30AM-12:30PM: Abstract Number: 2095

Patient Perceptions of an Osteoarthritis Management Program at a Midwest Medical Center

10:30AM-12:30PM: Abstract Number: 2088

Personalized Prediction of Pain and Function for Knee Osteoarthritis Patients 1 Year After Total Knee Arthroplasty Using Machine Learning

10:30AM-12:30PM: Abstract Number: 2109

Pincer Grip and Metacarpophalangeal Patterns Emerge as New Phenotypes of Hand Osteoarthritis Using a Data Driven Approach: Data from the Osteoarthritis Initiative

10:30AM-12:30PM: Abstract Number: 2090

Prevalence of Steatotic Liver Disease and Liver Fibrosis Among Patients with Osteoarthritis (OA)

10:30AM-12:30PM: Abstract Number: 2092

Remote-Delivered Tai Chi and Gut Microbiota in Osteoarthritis: A Randomized Mechanistic Trial

10:30AM-12:30PM: Abstract Number: 2103

Synovial Inflammation Is Increased in Females with Knee Osteoarthritis

10:30AM-12:30PM: Abstract Number: 2105

The Identity, Impact, and Management of OA and OA Pain from the Perspective of People with OA: A Systematic Literature Review of Qualitative Studies

10:30AM-12:30PM: Abstract Number: 2104

The Relationship of Soluble Biomarkers to OA Pain: A Systematic Literature Review

10:30AM-12:30PM: Abstract Number: 2093

Treatment of Advanced Knee OA with Lorecivivint Leads to Improved Long-Term Patient Acceptable Symptom State (PASS) Compared to Placebo: Data from Phase 3 Extension Trial

10:30AM-12:30PM: Abstract Number: 2102

Unraveling Knee Osteoarthritis Subtypes: Differential Effect of Oral Salmon Calcitonin Treatment

10:30AM-12:30PM: Abstract Number: 2098

Vitamin D Deficiency Is Associated with Progression of Radiographic Hand Osteoarthritis in a 6-year Follow-up of the Dong-gu Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].